### Thursday, September 15, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 PM-1:00 PM</td>
<td>Registration &amp; Poster Mounting</td>
<td></td>
</tr>
<tr>
<td>1:00 PM-1:10 PM</td>
<td>WELCOME TO HOUSTON</td>
<td>Jorge Cortes (Houston)</td>
</tr>
<tr>
<td>1:10 PM-1:20 PM</td>
<td>iCMLf – A REVIEW</td>
<td>Tim P. Hughes (Adelaide)</td>
</tr>
<tr>
<td>1:20 PM-1:30 PM</td>
<td>JANET ROWLEY PRIZE PRESENTATION</td>
<td>Rick Van Etten (Irvine)</td>
</tr>
<tr>
<td></td>
<td>Awardees 2016: Nora Heisterkamp (Los Angeles)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>John Groffen (Los Angeles)</td>
<td></td>
</tr>
<tr>
<td>1:30 PM-1:50 PM</td>
<td>SPECIAL LECTURE 1: (15’+ 5’ discussion)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Rick Van Etten (Irvine)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evaluation in leukemia research: from identification of the</td>
<td>Nora Heisterkamp (Los Angeles)</td>
</tr>
<tr>
<td></td>
<td>BCR/ABL fusion to carbohydrate-mediated protection by the</td>
<td>John Groffen (Los Angeles)</td>
</tr>
<tr>
<td></td>
<td>bone marrow microenvironment</td>
<td></td>
</tr>
<tr>
<td>1:50 PM-3:20 PM</td>
<td>SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2016 (12’ + 3’ discussion)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Danilo Perrotti (Baltimore), Stéphane Prost (Fontenay-aux-Roses)</td>
<td></td>
</tr>
<tr>
<td>1:50-2:05</td>
<td>MS4A3: a new player in CML stem cell survival and</td>
<td>Anna M. Eiring (Salt Lake City)</td>
</tr>
<tr>
<td></td>
<td>myeloid malignancies</td>
<td></td>
</tr>
<tr>
<td>2:05-2:20</td>
<td>Comprehensive analysis of the structural, biochemical and</td>
<td>Oliver Hantschel (Lausanne)</td>
</tr>
<tr>
<td></td>
<td>signaling differences of the p210 and p185 isoforms of Bcr-Abl in CML</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and B-ALL</td>
<td></td>
</tr>
<tr>
<td>2:20-2:35</td>
<td>CML stem cells are dependent on mitochondrial oxidative</td>
<td>G. Vignir Helgason (Glasgow)</td>
</tr>
<tr>
<td></td>
<td>metabolism for their survival</td>
<td></td>
</tr>
</tbody>
</table>
2:35-2:50 A potential role for interactions with the bone marrow microenvironment in regulating the aggressivity of BCR-ABL1 – T315I – positive chronic myelogenous leukemia
Daniela S. Krause (Frankfurt)

2:50-3:05 Natural killer cells and molecular relapse upon imatinib discontinuation in patients with chronic myeloid leukemia: results from the French multicenter Immunostim study
Delphine Réa (Paris)

3:05-3:20 Prediction for sustained deep molecular response of BCR-ABL levels in patients with chronic myeloid leukemia in chronic phase
Koji Sasaki (Houston)

3:20 PM-3:50 PM Coffee Break

3:50 PM-5:40 PM SCIENTIFIC SESSION 2: STEM CELLS AND THE MICROENVIRONMENT
Chair: Mirle Schemionek (Aachen)

3:50-4:10 Keynote Presentation (15’ + 5’ discussion)
Partners in crime: dissecting CML stem cells and microenvironmental interactions
Ravi Bhatia (Birmingham)

4:10-5:40 Selected Abstracts (12’ + 3’ discussion)
4:10-4:25 Leukomics: Bringing high-throughput stem cell data to the leukemia research community
Lorna Jackson (Glasgow)

4:25-4:40 Combined inhibition of beta-catenin signaling and Bcr-Abl tyrosine kinase synergistically targets blast crisis CML cells and stem/progenitor cells in vitro and in vivo
Bing Z. Carter (Houston)

4:40-4:55 Potential targeting Ph+ acute lymphoblastic leukemia stem and progenitor cells by modulating the CIP2A-SET-SETBP1 – mediated suppression of PP2A activity
Danilo Perrotti (Baltimore)

4:55-5:10 Phosphorylation of elf2alpha as novel mechanism regulating secretion of cytokines and matrix-modifying enzymes by CML cells to support the microenvironment changes and leukemia-stroma interactions
Katarzyna Piwocka (Warsaw)

5:10-5:25 The BMP pathway deregulations in the CML niche persist under tyrosine kinase inhibitors and induce LSC persistence
Elodie Grockiowki (Lyon)

5:25-5:40 CML-induced dysregulation of bone marrow skeletal stem cell subpopulations
Puneet Agarwal (Birmingham)

5:40 PM Poster Viewing and Refreshments

Friday, September 16, 2016

8:00 AM-10:00 AM WORKSHOP FOR NON-CLINICAL SCIENTISTS #1
SINGLE CELL APPROACHES
Chair: Jerry Radich (Seattle)

8:00-8:05 Introduction
8:05-8:30  Drop-seq analysis of early fate decisions in human hematopoiesis  Rahul Satija (New York)
8:30-8:40  General Discussion
8:40-9:05  Heterogeneity and population dynamics of the chronic myeloid leukemia microenvironment  Robert Welner (Birmingham)
9:05-9:15  General Discussion
9:15-9:40  Single-cell transcriptomics uncovers heterogeneity and distinct molecular signatures of therapy-resistant chronic myeloid leukemia stem cells  Adam Mead (Oxford)
9:40-9:50  General Discussion
9:50-10:00  Concluding Remarks

8:30 AM-10:00 AM  MORNING SATELLITE SYMPOSIUM #1 CEPHEID

10:00 AM-10:30 AM  Coffee Break
10:30 AM-11:50 AM  SCIENTIFIC SESSION 3: MOLECULAR BIOLOGY AND NEW TARGETS (1)
   Chair: Giovanni Martinelli (Bologna)
10:30-10:50  Keynote Presentation (15’ + 5’ discussion)
   ACTIW: a program to validate candidate molecules able to target minimal residual disease in CML  Philippe Rousselot (Versailles)
10:50-11:50  Selected Abstracts (12’ + 3’ discussion)
10:50-11:05  High or low BCR-ABL transcripts at diagnosis are associated with different phosphorylation of downstream targets and distinct short- and long-term proliferative potential  Paolo Vigneri (Catania)
11:05-11:20  Identification of imatinib-sensitizing genes in chronic myeloid leukemia with a genome-scale Crispr knock-out screen  Matthieu Lewis (Bordeaux)
11:20-11:35  Regulative loop between beta-catenin and protein tyrosine phosphatase receptor type gamma (PTPRG) in chronic myeloid leukemia  Luisa Tomasello (Verona)
11:35-11:50  Hypoxia inducible arginase ARG2 is required for the survival of acute and chronic myeloid leukemia cells  King Pan Ng (Singapore)
11:50 AM-12:10 PM  SPECIAL LECTURE 2: (15’ + 5’ discussion)
   Chair: Tessa Holyoake (Glasgow)
Leukemic stem cell interactions with the microenvironment: friend or foe?

Dominique Bonnet (London)

12:10 PM-1:45 PM  
*Lunch and Poster Viewing*

1:45 PM-3:05 PM  
**SCIENTIFIC SESSION 4: MOLECULAR BIOLOGY AND NEW TARGETS (2)**

*Chair: Oliver Hantschel (Lausanne)*

1:45-2:05  
**Keynote Presentation** *(15’ + 5’ discussion)*

Transcriptional control of metabolism in CML and lymphoid blast crisis  
Markus Müschen (San Francisco)

2:05-3:05  
**Selected Abstracts** *(12’ + 3’ discussion)*

2:05-2:20  
ABL1 kinase: the frenemy of hematopoietic cells  
Yashodhara Dasgupta (Philadelphia)

2:20-2:35  
SIRT1 and LSD1 competitively regulate KU70 functions in DNA repair and BCR-ABL mutation acquisition  
WenYong Chen (Duarte)

2:35-2:50  
Dynamic spectrum of somatic mutations in response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia  
Dennis Dong Hwan Kim (Toronto)

2:50-3:05  
Alternative telomere lengthening and genomic instability in chronic myeloid leukemia – the potential role of POT1 and RAP1  
Tomasz Stoklosa (Warsaw)

3:05 PM-3:35 PM  
*Coffee Break*

3:35 PM-3:55 PM  
**SPECIAL LECTURE 3** *(15’ + 5’ discussion)*

*Chair: Feyruz Rassool (Baltimore)*

Noncoding RNAs, myeloid transcription factors, and leukemia  
Daniel G. Tenen (Singapore)

3:55 PM-5:30 PM  
**SCIENTIFIC SESSION 5: MECHANISMS OF RESISTANCE**

*Chair: Andreas Hochhaus (Jena)*

3:55-4:15  
**Keynote Presentation** *(15’ + 5’ discussion)*  
Michael Deininger (Salt Lake City)

4:15-5:30  
**Selected Abstracts** *(12’ + 3’ discussion)*

4:15-4:30  
Resistance mechanisms of the new allosteric inhibitor ABL001  
Laura Eadie (Adelaide)

4:30-4:45  
Identification of genetic variants associated with imatinib resistance in chronic myeloid leukemia patients by a targeted sequencing approach  
Florence Lichou (Bordeaux)

4:45-5:00  
ABCC6 plays a significant role in the transport of nilotinib in both cell lines and primary patient cells, and may contribute to resistance  
Laura Eadie (Adelaide)

5:00-5:15  
Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia  
Wei Wang (Houston)

5:15-5:30  
Mechanism of oncogene addiction in CML  
Mohammad Azam (Cincinnati)

5:30 PM  
*Poster Walk 1 and Refreshments*
**Biology Poster Walk:** Anna Eiring (Salt Lake City) and G. Vignir Helgason (Glasgow)

**Clinical Poster Walk:** Dragana Milojkovic (London) and Javier Pinilla-Ibarz (Tampa)

---

**Saturday, September 17, 2016**

### 8:30 AM-11:00 AM  
**CLINICAL SYMPOSIUM ON MODERN DIAGNOSTICS**  
**Chair:** Tim P. Hughes (Adelaide)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:40</td>
<td>Welcome and Introduction</td>
<td></td>
</tr>
<tr>
<td>8:40-8:55</td>
<td>The role of cytogenetic monitoring in CML management in 2016</td>
<td>Jorge Cortes (Houston)</td>
</tr>
<tr>
<td>8:55-9:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:05-9:20</td>
<td>Molecular monitoring in CML – getting to a safe place</td>
<td>Martin Müller (Mannheim)</td>
</tr>
<tr>
<td>9:20-9:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:30-9:45</td>
<td>Molecular monitoring in the context of TFR</td>
<td>Susanne Saussele (Mannheim)</td>
</tr>
<tr>
<td>9:45-9:55</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9:55-10:10</td>
<td>Mutation screening – what is standard of care today and the role of new modalities</td>
<td>Simona Soverini (Bologna)</td>
</tr>
<tr>
<td>10:10-10:20</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:20-10:35</td>
<td>Biomarkers and response monitoring beyond PCR</td>
<td>Deborah White (Adelaide)</td>
</tr>
<tr>
<td>10:35-10:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:45-11:00</td>
<td><strong>Debate:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is monitoring as recommended by current guidelines applicable and necessary in standard care of patients with CML</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>For:</strong> Giuseppe Saglio (Turin)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Against:</strong> Charles Schiffer (Detroit)</td>
<td></td>
</tr>
</tbody>
</table>

### 9:00 AM-11:00 AM  
**WORKSHOP FOR NON-CLINICAL SCIENTISTS #2**  
**HUMANIZED MOUSE MODELS**  
**Chairs:** Ravi Bhatia (Birmingham), Brian Huntly (Cambridge)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00-9:05</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>9:05-9:30</td>
<td>Using engineered mice to express human genes to enhance human cell engraftment</td>
<td>Anthony Rongvaux (Seattle)</td>
</tr>
<tr>
<td>9:30-9:40</td>
<td>General Discussion</td>
<td></td>
</tr>
<tr>
<td>9:40-10:05</td>
<td>Coinjection of human mesenchymal cells to enhance human cell engraftment</td>
<td>Hind Medyof (Frankfurt)</td>
</tr>
<tr>
<td>10:05-10:15</td>
<td>General Discussion</td>
<td></td>
</tr>
<tr>
<td>10:15-10:40</td>
<td>Using mutant c-Kit to enhance human cell engraftment</td>
<td>Claudia Waskow (Dresden)</td>
</tr>
</tbody>
</table>
10:40-10:50 General Discussion
10:50-11:00 Concluding Remarks

11:00 AM-11:30 AM Coffee Break

11:30 AM-11:58 PM BRIEF ORAL COMMUNICATIONS (BIOLOGY) (4 slides/5’ + 2’ discussion)
Chair: Tomasz Skorski (Philadelphia)
11:30-11:37 Histone deacetylase inhibitors modulate DSB repair in leukemias by facilitating increased PARP1 entrapment to DSBs in chromatin Pratik Nagaria (Baltimore)
11:37-11:44 Anti-tumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors Riham Nasr (Beirut)
11:44-11:51 Tunneling nanotube communication in tyrosine kinase inhibitor treated chronic myeloid leukemia cells Maria Omsland (Bergen)
11:51-11:58 Novel hot spot mutations in BCR-ABL1: are we looking the right way to TKI resistance? Sabrina Pricl (Trieste)

11:58 PM-12:26 PM BRIEF ORAL COMMUNICATIONS (CLINICAL) (4 slides/5’ + 2’ discussion)
Chair: Stuart Goldberg (Hackensack)
11:58-12:05 Second generation TKIs provide a more effective treatment with higher persistence rates than imatinib in “real-world” newly diagnosed CML patients Inge G.P. Geelen (Dordrecht)
12:05-12:12 The dynamic of CML prevalence from relative survival and demographic data in France. History and forecast for the next decades Marc Delord (Paris)
12:12-12:19 Implementing a certified plasmid reference material for copy number calibration demonstrates good reporting correlation between %BCR-ABL/ABL (IS) and %BCR-ABL/ABL (Copy Number) in Xpert® BCR-ABL Ultra Gwo-Jen Day (Sunnyvale)
12:19-12:26 Adjuvant immunotherapy results in durable TKI-free responses in CML-CP patients Jonathan Webster (Baltimore)

12:30 PM-2:30 PM Lunch and Poster Viewing

1:00 PM-2:30 PM MID-DAY SATELLITE SYMPOSIUM #1 ALPINE TITLE

2:30 PM-3:50 PM SCIENTIFIC SESSION 6: BIOMARKERS
Chair: Deborah White (Adelaide)
2:30-2:50 Keynote Presentation (15’ + 5’ discussion)
Biomarkers for prognostic evaluation: how to identify the best? François Guilhot (Poitiers)
2:50 PM-3:50 PM Selected Abstracts (12’ + 3’ discussion)
2:50-3:05  BIM deletion polymorphism as a prognostic biomarker in conjunction with the EUTOS long-term survival (ELTS) score in Asian CML patients treated with imatinib  
Hein Than (Singapore)

3:05-3:20  Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to nilotinib therapy in early chronic phase chronic myelogenous leukemia (CML-CP)  
Dominik Wolf (Bonn)

3:20-3:35  Single-cell analysis reveals stem-cell program of CML stem cells  
Chinmay Rajiv Munje (Glasgow)

3:35 PM-4:05 PM  Coffee Break

4:05 PM-4:25 PM  SPECIAL LECTURE 4: (15’ + 5’ discussion)  
Chair: David Scheinberg (New York)

Towards identification and targeting of leukemic stem cells using humanized niche xenograft mouse models  
Jan Jacob Schuringa (Groningen)

4:25 PM-5:45 PM  SCIENTIFIC SESSION 7: THERAPEUTIC INTERVENTIONS  
Chair: Franck Nicolini (Lyon)

4:25-4:45  Keynote Presentation (15’ + 5’ discussion)  
From imatinib to...imatinib : CML treatment comes home, via stem cells and fatigue  
Carlo Gambacorti-Passerini (Monza)

4:45-5:00  Selected Abstracts (12’ + 3’ discussion)  
BP1001, a novel therapeutic for chronic myelogenous leukemia  
Ana Tari Ashizawa (Bellaire)

5:00-5:15  Long-term efficacy and safety of ponatinib in heavily pretreated leukemia patients: 4-year results from the pivotal phase 2 PACE trial  
Jorge Cortes (Houston)

5:15-5:30  Efficacy and safety following bosutinib dose reduction in patients with philadelphia chromosome-positive chronic myeloid leukemia  
Vamsi Kota (Atlanta)

5:30-5:45  Interferon alpha salvages recurrent or persisting post-transplant relapse of CML refractory to DLI and TKI producing sustained molecular remissions and operational cures  
John Barrett (Bethesda)

5:45 PM-5:55 PM  JOHN GOLDMAN PRIZE PRESENTATION  
Jorge Cortes (Houston)

Awardee 2016: Hagop Kantarjian (Houston)

5:55 PM-6:15 PM  SPECIAL LECTURE 5 (15’ + 5’ discussion)  
Chair: Jorge Cortes (Houston)

CML in 2016 – Progress and opportunities  
Hagop Kantarjian (Houston)

6:15 PM  Poster Walk 2 and Refreshments

- Biology Poster Walk: Anna Eiring (Salt Lake City) and G. Vignir Helgason (Glasgow)
- Clinical Poster Walk: Dragana Milojkovic (London) and Javier Pinilla-Ibarz (Tampa)
Sunday, September 18, 2016

7:00 AM-8:00 AM  FUN RUN - PRE-REGISTRATION IS REQUIRED

Get your day off to a great start! Join us for an early 5km run at Houston’s beautiful Memorial Park.

8:30 AM-10:05 AM  SCIENTIFIC SESSION 8: PREDICTORS AND MODELING OF RESPONSE
Chair: Javier Pinilla-Ibarz (Tampa)

8:30-8:50  Keynote Presentation (15’ + 5’ discussion)  Pierre Laneuville (Montreal)

8:50-10:05  Selected Abstracts (12’ + 3’ discussion)

8:50-9:05  Impact of early responses on 3-year outcomes in heavily pretreated CP-CML patients: landmark analyses in the pivotal ponatinib PACE trial  Martin C. Müller (Mannheim)

9:05-9:20  Acceptable molecular response of BCR-ABL levels in patients with chronic myeloid leukemia in chronic phase  Koji Sasaki (Houston)

9:20-9:35  Early response at 3 months with radotinib or imatinib in chronic myeloid leukemia from a randomized phase 3 trial (RERISE)  Young Rok Do (Daegu)

9:35-9:50  Predictors of stable deep molecular response in chronic phase CML patients treated with dasatinib or nilotinib after imatinib failure  Massimiliano Bonifacio (Verona)

9:50-10:05  Prognostic significance of treatment and response duration for successful stopping tyrosine kinase inhibitors chronic myeloid leukemia patients: results of the EURO-SKI trial  Susanne Saussele (Mannheim)

10:05 AM-11:10 AM  SCIENTIFIC SESSION 9: SAFETY, COST AND EXPERIENCE
Chair: François-Xavier Mahon (Bordeaux)

10:05-10:25  Keynote Presentation (15’ + 5’ discussion)  Jeffrey Lipton (Toronto)

10:25-11:10  Selected Abstracts (12’ + 3’ discussion)

10:25-10:40  Higher out-of-pocket expenses for tyrosine kinase inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia  Qian Jiang (Beijing)

10:40-10:55  CML treatment in Dutch hospitals with low patient volumes is associated with a substandard quality of molecular response monitoring  Inge G.P. Geelen (Dordrecht)

10:55-11:10  Arterio-thrombotic events among chronic myeloid leukemia patients on tyrosine kinase inhibitors  Hycienth Ahaneku (Houston)

11:10 PM-11:20 PM  iCMLf PRIZE PRESENTATION:
Awardee 2016: Susan Branford (Adelaide)
11:20 PM-11:40 PM  **SPECIAL LECTURE 6: (15' + 5' discussion)**  
Chair: Tim P. Hughes (Adelaide)  
Challenges for monitoring patients in emerging economic regions  
Susan Branford (Adelaide)  

11:40 AM-12:10 PM  **DEBATE: TFR ATTEMPTS – MORE DOWNSIDE THAN BENEFITS**  
Chair: Pierre Laneuville (Montreal)  
For: Michael Mauro (New York)  
Against: Delphine Réa (Paris)  

12:10 PM  **Meeting Adjourned**